

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Miskowiak, KW;Seeberg, I;Jensen, MB;Balanzá-Martínez, V;del Mar Bonnin, C;Bowie, CR;Carvalho, AF;Dols, A;Douglas, K;Gallagher, P;Hasler, G;Lafer, B;Lewandowski, KE;López-Jaramillo, C;Martinez-Aran, A;McIntyre, RS;Porter, RJ;Purdon, SE;Schaffer, A;Stokes, P;Sumiyoshi, T;Torres, IJ;Van Rheenen, TE;Yatham, LN;Young, AH;Kessing, LV;Burdick, KE;Vieta, E

Title:

Randomised controlled cognition trials in remitted patients with mood disorders published between 2015 and 2021: A systematic review by the International Society for Bipolar Disorders Targeting Cognition Task Force

Date:

2022-06-01

Citation:

Miskowiak, K. W., Seeberg, I., Jensen, M. B., Balanzá-Martínez, V., del Mar Bonnin, C., Bowie, C. R., Carvalho, A. F., Dols, A., Douglas, K., Gallagher, P., Hasler, G., Lafer, B., Lewandowski, K. E., López-Jaramillo, C., Martinez-Aran, A., McIntyre, R. S., Porter, R. J., Purdon, S. E., Schaffer, A., ... Vieta, E. (2022). Randomised controlled cognition trials in remitted patients with mood disorders published between 2015 and 2021: A systematic review by the International Society for Bipolar Disorders Targeting Cognition Task Force. *Bipolar Disorders*, 24 (4), pp.354-374. <https://doi.org/10.1111/bdi.13193>.

Persistent Link:

<https://hdl.handle.net/11343/301784>

License:

CC BY

Randomised controlled cognition trials in remitted patients with mood disorders published between 2015 and 2021: A systematic review by the International Society for Bipolar Disorders Targeting Cognition Task Force

Kamilla W. Miskowiak^{1,2}  | Ida Seeberg^{1,2} | Mette B. Jensen¹ | Vicent Balanzá-Martínez³ | Caterina del Mar Bonnin⁴ | Christopher R. Bowie⁵  | Andre F. Carvalho⁶  | Annemieke Dols⁷  | Katie Douglas⁸  | Peter Gallagher⁹ | Gregor Hasler¹⁰ | Beny Lafer¹¹  | Kathryn E. Lewandowski^{12,13}  | Carlos López-Jaramillo¹⁴ | Anabel Martínez-Aran⁴ | Roger S. McIntyre¹⁵  | Richard J. Porter⁸  | Scot E. Purdon¹⁶ | Ayal Schaffer¹⁷  | Paul Stokes¹⁸  | Tomiki Sumiyoshi¹⁹  | Ivan J. Torres²⁰ | Tamsyn E. Van Rheenen^{21,22} | Lakshmi N. Yatham²⁰ | Allan H. Young¹⁸ | Lars V. Kessing^{1,23}  | Katherine E. Burdick^{13,24}  | Eduard Vieta⁴ 

¹Copenhagen Affective Disorder Research Centre (CADIC), Psychiatric Centre Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark

²Department of Psychology, University of Copenhagen, Copenhagen, Denmark

³Teaching Unit of Psychiatry and Psychological Medicine, Department of Medicine, University of Valencia, CIBERSAM, Valencia, Spain

⁴Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain

⁵Department of Psychology, Queen's University, Kingston, Canada

⁶IMPACT Strategic Research Centre (Innovation in Mental and Physical Health and Clinical Treatment), Deakin University, Geelong, Vic., Australia

⁷Department of Old Age Psychiatry, GGZ in Geest, Amsterdam UMC, Location VUmc, Amsterdam Neuroscience, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands

⁸Department of Psychological Medicine, University of Otago, Christchurch, New Zealand

⁹Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle-upon-Tyne, UK

¹⁰Psychiatry Research Unit, University of Fribourg, Fribourg, Switzerland

¹¹Bipolar Disorder Research Program, Institute of Psychiatry, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil

¹²McLean Hospital, Schizophrenia and Bipolar Disorder Program, Belmont, Massachusetts, USA

¹³Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA

¹⁴Research Group in Psychiatry, Department of Psychiatry, Universidad de Antioquia, Medellín, Colombia

¹⁵Mood Disorders Psychopharmacology Unit, Brain and Cognition Discovery Foundation, University of Toronto, Toronto, Canada

¹⁶Department of Psychiatry, University of Alberta, Edmonton, Canada

¹⁷Department of Psychiatry, University of Toronto

¹⁸Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK

¹⁹Department of Preventive Intervention for Psychiatric Disorders, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan

²⁰Department of Psychiatry, University of British Columbia, Vancouver, Canada

²¹Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne, Carlton, Australia

²²Centre for Mental Health, Faculty of Health, Arts and Design, Swinburne University, Australia

²³Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

²⁴Department of Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts, USA

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2022 The Authors. *Bipolar Disorders* published by John Wiley & Sons Ltd.

Correspondence

Kamilla Woznica Miskowiak, Head of Neurocognition and Emotion in Affective Disorders (NEAD) Group, CADIC, Psychiatric Centre Copenhagen, Copenhagen University Hospital, Blegdamsvej 9, DK-2100 Copenhagen. Email: Kamilla.miskowiak@regionh.dk

Abstract

Background: Cognitive impairments are an emerging treatment target in mood disorders, but currently there are no evidence-based pro-cognitive treatments indicated for patients in remission. With this systematic review of randomised controlled trials (RCTs), the International Society for Bipolar Disorders (ISBD) Targeting Cognition Task force provides an update of the most promising treatments and methodological recommendations.

Methods: The review included RCTs of candidate pro-cognitive interventions in fully or partially remitted patients with major depressive disorder or bipolar disorder. We followed the procedures of the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) 2020 statement. Searches were conducted on PubMed/MEDLINE, PsycInfo, EMBASE and Cochrane Library from January 2015, when two prior systematic reviews were conducted, until February 2021. Two independent authors reviewed the studies with the Revised Cochrane Collaboration's Risk of Bias tool for Randomised trials.

Results: We identified 16 RCTs ($N = 859$) investigating cognitive remediation (CR; $k = 6$; $N = 311$), direct current or repetitive magnetic stimulation ($k = 3$; $N = 127$), or pharmacological interventions ($k = 7$; $N = 421$). CR showed most consistent cognitive benefits, with two trials showing improvements on primary outcomes. Neuromodulatory interventions revealed no clear efficacy. Among pharmacological interventions, modafinil and lurasidone showed early positive results. Sources of bias included small samples, lack of pre-screening for objective cognitive impairment, no primary outcome and no information on allocation sequence masking.

Conclusions: Evidence for pro-cognitive treatments in mood disorders is emerging. Recommendations are to increase sample sizes, pre-screen for impairment in targeted domain(s), select one primary outcome, aid transfer to real-world functioning, investigate multimodal interventions and include neuroimaging.

KEYWORDS

bipolar disorder, cognitive impairment, intervention, ISBD Task Force, major depressive disorder, randomised controlled trials, recommendations, systematic review

1 | INTRODUCTION

Cognitive impairments in attention, memory and executive functions occur across several neuropsychiatric disorders, including bipolar disorder (BD) and major depressive disorder (MDD). The profile of the cognitive impairment is similar across these disorders, involving non-specific deficits in several domains,¹⁻³ although the severity of impairment is greater in BD than in MDD.⁴ Cognitive impairments are not reversed by antipsychotic, antidepressant or mood-stabilising treatments but persist during clinical remission in a substantial subset of patients⁵⁻⁸ and are further compounded by alcohol/drug misuse and medical comorbidities.⁹⁻¹¹ This contributes to socio-occupational disability,¹²⁻¹⁵ the largest socio-economic burden of these disorders.^{16,17} Cognitive impairment is also associated

with poorer overall treatment response in mood disorders^{18,19} including increased risk of manic relapse in BD.²⁰⁻²² Given this, targeting cognitive impairment is a pressing treatment priority in mood disorders.^{23,24} Accordingly, the field has undertaken a number of treatment trials over the last two decades, which aimed to improve cognition in these patients. Notwithstanding these efforts, there are still no clinically available pro-cognitive treatments with replicated efficacy in remitted patients with BD or MDD.²⁵⁻²⁸

Two systematic reviews from 2015 of randomised controlled trials (RCTs) in BD and MDD, respectively, found promising preliminary evidence for a series of behavioural, pharmacological and other biological interventions.^{26,27} In BD, cognitive remediation (CR) and pharmacological interventions with either mifepristone, galantamine, insulin, erythropoietin (EPO), *Withania somnifera* or citicoline

improved either a single or a subset of cognition measures, with effects of CR, mifepristone and EPO prevailing after Bonferroni correction.²⁶ In MDD, preliminary effects were also observed in response to CR and EPO and additionally in trials of vortioxetine and transcranial direct current stimulation (tDCS).²⁷ The risk of bias for the 41 RCTs included in these two reviews^{26,27} was rated as high for 18 (44%), as moderate or unclear for 18 (44%) and low for only five (12%) of studies. Further, pseudospecificity (i.e., non-specific cognitive improvement due to treatment-associated decrease in mood symptoms) could not be ruled out because a substantial proportion of the identified RCTs were conducted in symptomatic patients (86% of trials in MDD and 37% in BD). A subsequent systematic review of RCTs in BD also concluded that the evidence for pro-cognitive effects was mixed and uncertain given a scarcity of studies, small samples and high or unclear risk of bias in most trials.²⁹ More recently, a meta-analysis identified seven RCTs of CR or functional remediation.³⁰ While cognitive gains were reported by most studies, the pattern of the improvements was heterogenous and not replicated across trials. All RCTs were evaluated as having moderate or high risk of bias. Taken together, the evidence for efficacy on cognition of behavioural, pharmacological and other biological interventions in mood disorders is mixed. Importantly, the reviews identified a series of common methodological issues that may have attenuated assay sensitivity in the trials.^{26,27,30}

In prior work by the International Society for Bipolar Disorders (ISBD) Targeting Cognition Task Force, we examined the possible barriers to successful cognition trial outcomes and outlined methodological areas where a consensus was not yet established, including the need for pre-screening for cognitive impairments, how to define efficacy outcomes, how to measure functional implications and how to manage mood symptoms and concomitant medications.²⁵ Key recommendations from this work encouraged future studies to: (i) enrich samples for objectively measured cognitive impairments on neuropsychological tests, (ii) select global cognition as the primary outcome in general except for cases where there is evidence that a treatment is likely to target a specific cognitive domain, (iii) include a functional measure as co-primary or key secondary outcome and (iv) enrol fully or partially remitted patients to avoid potential pseudospecificity issues due to concomitant mood improvements in response to the interventions, and (v) exclude patients with current substance or alcohol use disorders, neurological disease or unstable medical illness. Additionally, the Task Force suggested (vi) the implementation of neuroimaging assessments when possible and the systematic application of multimodal treatment approaches.²⁵

The present systematic review by the ISBD Targeting Cognition Task Force is an update of the two previous systematic reviews of RCTs conducted in 2015 for BD and MDD, respectively.^{26,27} Here, we focus on evidence from studies in *fully or partially remitted* patients to avoid pseudospecificity issues and examine efficacy on the trait-related cognitive impairments, in line with the Task Force recommendations.²⁵ The rationale for including RCTs published after January 2015 was to avoid overlap with the previous systematic reviews and to examine the most recent evidence and quality of

the recent trials with the aim to update the Task Force recommendations. Specifically, with the current review, we aim to: (i) provide an update and critically evaluate the quality of the evidence from RCTs of candidate pro-cognitive treatments *across mood disorders* in patients who are in full or partial remission published between January 2015 and February 2021, (ii) provide updated methodological recommendations, and (iii) outline the most promising targets for pro-cognitive interventions. We did not conduct a quantitative meta-analysis of the available evidence because of the discrepancies between types of interventions (including distinct psychological and pharmaceutical treatments), study designs (e.g., single- vs. double-blind) and treatment schedules (single dose vs. months of treatment). Instead, this systematic review focuses on an evaluation of research design, methods and outcome criteria in the identified RCTs based on the Revised Cochrane Collaboration's Risk of Bias tool for Randomised trials (RoB2) and provides a discussion of the most promising targets for future research into pro-cognitive interventions in mood disorders.

2 | EXPERIMENTAL PROCEDURES

2.1 | Data sources

This systematic review followed the procedures of the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) 2020 statement.³¹ A comprehensive systematic computerised search was performed on the PubMed/MEDLINE, PsycInfo, EMBASE and Cochrane Library databases from 1st January 2015 to 28th February 2021. The search profile included four elements "Mood disorder", "Cognition", "Intervention" and "RCT" with each of their combinations and alternative keywords in the respective databases (see Supplementary material for details on the search profile). A protocol of the review was registered a priori in the online database, PROSPERO (registration number: CRD-42021222836).

The initial search criteria were defined in accordance with the PICO framework (Population, Intervention, Comparison, Outcome). The clinical question was: In fully or partially remitted MDD or BD patients (population), are there any pharmacological or psychological pro-cognitive interventions (interventions) that, when compared with either a passive control group (a waitlist condition with treatment as usual; TAU) or an active control group receiving another pro-cognitive intervention (comparison), can improve cognitive functions (primary or secondary outcome)?

We included only original peer reviewed RCTs that aimed to improve objectively measured cognition through psychological, behavioural, pharmacological or other biological interventions in patients with MDD or BD in full or partial remission. Eligible reports involved (a) adult individuals (age ≥ 18) meeting either ICD or DSM diagnostic criteria for MDD or BD I or II (confirmed through a validated structured diagnostic interview) who were in *full or partial remission* at the time of baseline testing, as reflected by either Hamilton Depression Rating Scale 17-items (HDRS-17) score ≤ 16

or Montgomery-Asberg Depression Rating Scale (MADRS) <10 and - for BD samples - Young Mania Rating Scale (YMRS) score ≤14; (b) RCTs that investigated changes in cognition pre- and post-intervention, with cognition as either a primary or secondary outcome; (c) RCTs reporting on primary prospective trial outcomes (i.e. not post-hoc analyses of already published articles); (d) peer-reviewed studies defined both at the journal websites and noted in the article with information on when it was received, revised and accepted; (e) articles published in English only. We excluded articles that: (i) examined samples with several diagnoses unless data for MDD or BD were reported separately, (ii) were non-randomised trials or otherwise experimental trials, or (iii) were meeting abstracts, meta-analyses, reviews and case reports. No specific criteria were applied to the format of the control arms because the RCTs involved diverse psychological and biological interventions and with different matched control conditions (e.g. placebo, TAU etc.).

2.2 | Study selection

Two authors (IS and MBJ) independently performed a primary title/abstract screening for potentially eligible articles and, following this, a secondary full-text screening was conducted. A hand-search was performed as well by tracking and screening citations in the included articles for eligible articles. In all phases, all articles were considered in accordance with inclusion/exclusion criteria. No automation tools were used in the process. Interrater reliability was measured as percentage agreement, calculated as the number of *agreements* divided by the *total number of screened articles*. Agreement between the two authors was high (primary screening: 92%; secondary screening: 93%). Disagreements were discussed, and a consensus was reached in all cases through discussions with another author (KWM). Two authors (IS and KWM) extracted the measures of interest and summarised these in Tables 1 and 2. The data items were predefined according to the aims of the review and included the following: Authors, year of publication, study design, comparison, group, age, gender, mood state at entry, neurocognitive outcome measures and main findings. The syntheses of the included studies were predefined according to type of intervention, i.e. studies investigating the effect of cognitive remediation treatments (Table 1) and studies investigating the effect of pharmacological or brain stimulation treatments (Table 2).

2.3 | Risk of bias assessment

The risk of bias within and across the included randomised controlled studies was assessed by two authors (IS and KWM) according to the Revised Cochrane Collaboration's Risk of Bias tool for Randomised trials (RoB2) (<https://sites.google.com/site/riskofbiastool/welcome/rob-2-0-tool/current-version-of-rob-2>). The RoB2 assessment tool provided by Cochrane was used independently by the two authors. Table 2 displays the RoB2 evaluations of the included RCTs. To find

any missing information in the included trials, additional searches for registered RCTs were performed on clinicaltrials.gov, and a search for published study protocols was also performed on relevant search engines. The PRISMA 2020 checklist was completed (supplementary material).

3 | RESULTS

3.1 | Study characteristics

The systematic search, together with the additional hand-search, identified 2907 articles (after removal of duplicates) that were included for title/abstract screening (primary screening). Of these, 63 were evaluated for eligibility via a full-text reading (secondary screening). This resulted in the inclusion of 16 articles that met the inclusion criteria (see Figure 1). Tables 1 and 2 display the characteristics of the identified RCTs investigating potential prognostic psychological or biological treatments in patients with MDD or BD in full or partial remission ($N = 859$). Six studies investigated cognitive remediation (CR) interventions ($N = 311$),³²⁻³⁷ three studies investigated transcranial current or repetitive magnetic stimulation ($N = 127$)³⁸⁻⁴⁰ and seven studies investigated pharmacological treatments ($N = 421$)⁴¹⁻⁴⁷ of which three received support from the pharmaceutical industry.^{44,45,47} Five (31%) studies employed pre-screening of objective cognitive impairments.^{34,35,44,46,47} Applied criteria in trials with global cognition as the primary outcome^{34,35,46,47} were impairments on either: a global cognitive composite score,^{34,35,46} minimum two cognitive tests^{34,35} or one of two tests.⁴⁷ In a trial with a single cognitive domain (psychomotor speed) as the primary outcome, patients were enriched for deficits in that domain.⁴⁴ Eight studies included additional assessments of psychosocial function,^{32-35,37,44,47,48} three studies of functional capacity^{33,35,37} and six of subjective cognitive difficulties.^{35,37,43-45,47}

3.2 | Candidate cognitive remediation interventions

Six studies examined the effect of CR as an add-on to pharmacotherapy in partially remitted MDD or BD patients with samples ranging from $N = 22-75$ (Table 1). Of these, three studies evaluated computerised CR interventions.^{33,36,37} The first study investigated the effects of 70 hours of computerised CR ($n = 39$) relative to a computer control programmes ($n = 33$) three times weekly over 24 weeks in BD³³ with global cognition as the primary outcome. The treatment adherence was high (96%). The active group showed significantly greater improvement with a large effect size than the control group in the primary global MCCB cognitive composite outcome in the absence of changes in subsyndromal mood symptoms. A treatment-related improvement of a large effect size was also observed in the MCCB visual memory test, but not the six other tests.

No corresponding improvement of psychosocial function or functional capacity was observed.

The second study assessed the impact of 20 hours of computerised CR over 5 weeks in MDD ($n = 11$) compared with a computer control programme ($n = 11$).³⁶ It was not specified which cognition measure was the primary outcome, and psychosocial function was not investigated. Ninety-five % of the participants completed the study. Computerised CR resulted in significantly greater improvement than the control treatment across divided attention and switching, verbal working memory, planning skills and verbal memory (on five of 11 measures; effect sizes not provided), in the absence of changes in subsyndromal mood symptoms. Of these, all but "divided attention" and "switching" prevailed after Bonferroni correction.

The third study examined the effects of 20–30 h of computerised metacognition-informed, therapist-led CR over 12 weeks in BD ($n = 29$) compared with TAU ($n = 31$) on cognitive functions, with psychomotor speed (Digit Symbol Substitution Test; DSST) specified as the primary outcome.³⁷ The study completion rate was 88%. Patients in the CR group showed no greater improvement than the TAU group immediately after treatment in the primary cognition outcome or in a global cognition composite based on tests of verbal learning and memory, working memory and executive functions (for details, see Table 1). However, CR-related improvements with moderate effect sizes were seen on tests of working memory, IQ and executive function (three of nine cognition measures), which all prevailed at a 3-month follow-up assessment. Subsyndromal symptoms were similar between groups, although the CR group had slightly higher subsyndromal depression symptoms at the 3-month follow-up. The observed cognitive improvements would, however, not have survived Bonferroni correction for multiple comparisons across the nine cognition measures. Notably, CR improved psychosocial functions and functional capacity, and the effects on psychosocial functions prevailed at a 3-month follow-up.

Three studies involved computerised training combined with group-based CR sessions to aid the transfer of acquired skills to daily life cognitive challenges.^{32,34,35} The first study examined the effects of 15 sessions of CR conducted over 5 weeks in MDD with three weekly sessions in an individualised training format that targeted patients' particular deficits ($n = 20$) or in a generalised training format ($n = 18$) in comparison with TAU ($n = 19$).³⁴ Improvement of a global cognition composite was pre-specified as the primary outcome, while attention, processing speed, learning and memory, and executive functioning were secondary outcomes. Ninety-two percent of the participants completed the study. No treatment-related improvement of the primary global cognition outcome was observed. Regarding the secondary cognition outcomes, the two CR groups showed greater improvement than the control group in attention with a large effect size, but not in any other cognition measures. CR-treated patients also showed improved self-reported psychosocial functioning in the absence of significant changes in subsyndromal mood symptoms.

The second study³² investigated the effects of 12 sessions of group-based CR in BD ($n = 20$) vs. TAU ($n = 19$) with cognition being the secondary outcome (time to relapse was the primary outcome). CR improved response times, visual memory and some aspects of facial expression recognition, of which the effect on visual memory would have survived Bonferroni correction for multiple comparisons. No CR-related improvement was observed in functioning or subjective cognition, whereas changes in subsyndromal mood symptoms were not reported.

The third study examined the effects of group-based action-based CR (ABCR) conducted in twice weekly sessions over 10 weeks ($n = 32$ BD) compared with 10 weekly unstructured control group meetings supervised by a therapist ($n = 29$ BD). A global cognition measure was defined as the primary outcome, executive function (One Touch Stocking of Cambridge; OTS) and psychosocial function as secondary outcomes and additional cognition measures, functional capacity and subjective cognitive difficulties as tertiary (exploratory) outcomes.³⁵ Ninety-five percent of the participants completed the study. No significant treatment-related improvement was found on the global cognition outcome. However, the ABCR group displayed significantly greater improvement than the control group in the secondary executive function outcome with a large effect size, which prevailed after adjustment for multiple comparisons. Additional moderate-to-large ABCR-related improvement was observed on verbal learning and memory, although this did not survive adjustment for multiple comparisons across all tertiary outcomes. Finally, ABCR-treated patients reported improved subjective cognitive functioning in daily life – but showed no change in psychosocial function or functional capacity – compared with the control group. The effects occurred in the absence of treatment-related changes in mood symptoms.

In summary, all six CR interventions showed promising results; one study was positive, as indicated by significant treatment effects on the primary (global) cognition outcome³³; another study – with no pre-specification of which cognition outcome was primary – showed improvements in 5 of 11 cognition measures, of which four would have survived Bonferroni correction.³⁶ The final four studies^{32,34,35,37} found no treatment benefits on the primary cognition outcomes but all revealed improvements in multiple secondary and tertiary cognition measures. Importantly, participants' completion rates were high (88%–96%) in all studies, but one (65%)³² indicating good feasibility of CR in general. Three of the CR interventions – each of which involved explicit therapist techniques to facilitate transfer of cognitive skills to daily life – also improved either subjective cognitive functioning, psychological functioning or functional capacity.^{34,35,37}

3.3 | Other candidate biological interventions involving stimulation of the cortex

Three studies examined the cognitive benefits of transcranial direct current stimulation (tDCS) or repetitive transcranial magnetic

TABLE 1 Studies investigating the effect of randomised controlled trials of cognitive remediation treatments across patients with mood disorders in full or partial remission published between January 2015 and February 2021

| Author | Study design | Comparison (intervention/Control) | Group | Age (mean ± SD/median [IQR]) | Gender (% F) | Mood state at entry (scale, mean ± SD/median [IQR]) | Neurocognitive outcome measures | Main findings |
|---------------------------|--------------------|--|----------------|------------------------------|--------------|---|---|--|
| Lewandowski et al. (2017) | RCT (Double-blind) | 70-hours of Computerised Cognitive Remediation | 39 BD | 29.3 ± 7.5 | 51% | MADRS 1.8 ± 7.5 YMRS 5.6 ± 4.9 | Primary outcome: The MCCB composite Additional outcomes: The 10 individual MCCB tests measuring processing speed, attention, working memory, verbal learning, visual learning, problem solving and social cognition | Linear mixed effects models revealed significant group-by-time interactions at post-treatment for the cognitive composite and visual learning and memory and a trend for processing speed indicating significant improvements of cognitive remediation therapy over control |
| Semkowska et al. (2017) | RCT | 5 weeks (20-hours) of Computerised Cognitive Remediation | 11 MDD | 45.9 ± 6.7 | 82% | HDRS 4.5 ± 2.3 | Primary outcome: Not specified Additional outcomes: 11 tests that tapped into: psychomotor speed (DSST); divided attention (the d2 Selective attention test); auditory attention (the Digit Span Forward); verbal working memory (the Digit Span Backward); verbal learning and retention (the Logical memory-I&II); visual learning, immediate recall and retention. The Delis-Kaplan Executive Function System's subtests were also used, including the assessment of the following executive functions: verbal fluency (three consecutive categories) for self-regulation under external constraints, fluency switching for mental flexibility, towers for planning | Between-group ANOVA revealed significant group-by-time interactions at post treatment in divided attention, verbal working memory, and planning, as well as on non-targeted domains including long-term verbal memory and switching organisation of own thinking abilities (five of 11 measures) |
| Gomes et al (2019) | RCT (Single-blind) | 12 sessions of group-based Cognitive Remediation | 20 BD 19 BD | 42.7 ± 10.2 42.5 ± 10.2 | 80% 58% | N.I. N.I. | Cognition was secondary outcomes*: 10 neurocognitive tests from the CANTAB including 27 measures: MOT, RVP, RTI, SSP, SWM, OTS, PRM, DMS, AST, ERT *The primary outcome was time to first full mood episode | The effect on the primary outcome was not reported CR had no effect on quality of life or functioning Independent-sample Student's t-tests or Mann-Whitney tests of differential change between groups over time showed CR-related improvement in five cognition measures, tapping into response times and visual memory and facial expression recognition |

TABLE 1 (Continued)

| Author | Study design | Comparison (intervention/Control) | Group | Age (mean \pm SD/median [IQR]) | Gender (% F) | Mood state at entry (scale, mean \pm SD/median [IQR]) | Neurocognitive outcome measures | Main findings |
|--------------------------|--------------------|--|----------------------------|---|-------------------|---|---|--|
| Strawbridge et al (2020) | RCT (Single-blind) | 12 weeks of Metacognition-informed, therapy-led, computerised cognitive remediation therapy | 29 BD | 43 [19] | 72% | HDRS 4 [4] YMRS 2 [3] | Primary outcome: Psychomotor speed (DSST) Additional outcomes: Processing speed and attention (The Digit symbol substitution test and the Symbol search test); working memory (digit span); verbal learning (Verbal paired associates I); memory (verbal paired associates II); current IQ (WAIS); verbal fluency (FAS); executive function (Hotel test) | Linear mixed effects models revealed no significant group-by-time interaction in the primary cognition outcome (DSST) or in global cognition from pre- to post-treatment. However, CRT-related improvements were seen on tests of working memory, IQ and executive function (three of nine cognition measures) |
| Listunova et al. (2020) | RCT (Single-blind) | 5 weeks (3 \times weekly) of Individualised Cognitive remediation 5 weeks (3 \times weekly) of Generalised Cognitive remediation TAU | 20 MDD 18 MDD 19 MDD | 45.9 \pm 11.3 45.3 \pm 15.1 44.9 \pm 10.3 | 75% 78% 68% | HDRS 9.2 \pm 4.1 HDRS 8.7 \pm 4.8 HDRS 11.8 \pm 4.8 | Primary outcome: A global cognitive composite score Additional outcomes: Tests tapping into information processing speed (The Trail Making A and Zahlen Digit Symbol Coding), attention (Alertness, Divided Attention and Selective Attention from the Vienna Test System), learning and memory (CVLT and Figural Memory Test), executive functions (Inhibition, The Trail Making-B, Tower of London-F, N-back verbal from the Vienna Test System) | No effect was observed on the primary composite cognition measure However, general linear models revealed significant group-by-time interactions at post-treatment for attention, showing that the two active groups improved relative to the TAU group |

TABLE 1 (Continued)

| Author | Study design | Comparison (intervention/Control) | Group | Age (mean \pm SD/median [IQR]) | Gender (% F) | Mood state at entry (scale, mean \pm SD/median [IQR]) | Neurocognitive outcome measures | Main findings |
|-------------------|--------------------|--|-------|----------------------------------|--------------|---|---|--|
| Ott et al. (2020) | RCT (Single-blind) | 10 weeks (2 \times weekly) of Action-Based Cognitive Remediation Therapy | 32 BD | 36[20] | 72% | HDRS 6[4] YMRS 1.5[5] | Primary outcome: A global cognitive composite of: The Rey auditory verbal learning test (total recall); RBANS coding; Verbal fluency letter D; WAIS-III letter-number sequencing; Trail Making B; and the following Rapid Visual Processing (RVP) test from CANTAB Secondary cognition outcome: Executive function (One Touch Stocking of Cambridge) | No significant improvement was observed in the primary cognitive composite score. However linear mixed effects models revealed significant group-by-time interactions at post-treatment on executive functioning (secondary outcome), which remained significant following adjustment for multiple comparisons across the secondary outcomes |
| | | 10 weeks (1 \times weekly) of Control Treatment | 29 BD | 37[22] | 76% | HDRS 6[4] YMRS 1[5] | Tertiary outcomes: Individual measures comprising the primary outcome plus additional RAVLT measures, Verbal fluency letter S, Trail Making A, spatial working memory (CANTAB), RBANS digit span | |

Abbreviations: N.I., No information; BD, Bipolar Disorder; MDD, Major Depressive Disorder; F, Female; HC, healthy controls; HDRS, Hamilton depression rating scale; YMRS, Young Mania rating scale; IQR, Inter quartile range; IU, International units; RCT, Randomised controlled trial; SD, standard deviation; TAU, Treatment as usual; MCCB, MATRICS Consensus Cognitive Battery; RBANS, Repeatable Battery for the Assessment of Neuropsychological Status; DSST, Digit Symbol Substitution Test; CANTAB, Cambridge Neuropsychological Test Automated Battery; CVLT, California Verbal Learning Test; MOT; Motor Screening Task; RVP, Rapid Visual Information Processing; RTI, Reaction Time; SSP, Spatial Span; SWM, Spatial Working Memory; OTS, One Touch Stockings of Cambridge; PRM: Pattern Recognition Memory; DMS, Delayed Matching to Sample; AST, Attention Switching Task; ERT, Emotion Recognition Task.

TABLE 2 Studies investigating the effect of randomised controlled trials of pharmacological or brain stimulation treatments across patients with mood disorders in full or partial remission published between January 2015 and February 2021

| Author | Study design | Comparison (intervention/control) | Group | Age (mean \pm SD/median [IQR]) | Gender (% F) | Mood state at entry (scale, mean \pm SD/median [IQR]) | Neurocognitive outcome measures | Main findings |
|---|------------------------------|---|------------------------|-----------------------------------|--------------|--|---|--|
| Transcranial current and repetitive transcranial magnetic stimulation | | | | | | | | |
| Bersani et al. (2017) | RCT (Double-blind) | 15 sessions over 3 weeks Prefronto-Cerebellar Transcranial Direct Current stimulation | 21 BD | 48.1 \pm 10.7 | 38% | HDRS 4.7 \pm 1.8 YMRS 3.9 \pm 1.2 | Primary outcome: Not defined Additional cognition outcomes: Sustained attention (Trail Making Test-A); executive functioning (Wisconsin Card Sorting Test, Trail Making Test-B, Rey Complex Figure Test copy version); visuo-spatial memory (Rey Complex Figure Test delay recall) | Between-group ANOVA revealed significant group-by-time interactions for on executive function and visuospatial memory (two of five cognitive outcomes) |
| Kumar et al. (2020) | RCT (Double-blind) | 10 sessions over 2 weeks, Bilateral Dorsolateral Prefrontal Cortex Anodal Transcranial Direct Current stimulation | 18 MDD | 49.2 \pm 10.2 66.3 \pm 5.8 | 71% 72% | HDRS 4.7 \pm 1.7 YMRS 4.4 \pm 1.4 MADRS 2.8 \pm 2.53 | Primary outcome: Global cognitive composite. Additional outcomes: Working memory (Computerised N-back task), attention and psychomotor speed (Trail Making A, DSST), learning and memory (CVLT and Brief Visuospatial Memory Test) executive functions (Stroop Test) neuropsychological Screening, COWAT, Trail Making B, visuospatial skills (Clock Drawing Test) | No significant findings |
| Yang et al. (2019) | RCT (Single-blind) | 10 sessions over 2 weeks High-frequency repetitive transcranial magnetic stimulation | 25 BD | 28.6 \pm 8.1 | 52% | HDRS 4.8 \pm 2.8 YMRS 0.8 \pm 1.1 | Primary outcome: Not specified Additional outcomes: 10 tests from the MCCB measuring processing speed, attention, working memory, verbal learning, visual learning, problem solving, and social cognition | Between-group ANOVA revealed significant group-by-time interactions for working memory and speed of processing (two of 10 measures) |
| Pharmacological Interventions | | | | | | | | |
| Alda et al. (2017) | RCT crossover (Double-blind) | 12 weeks of Methylene blue (195 mg) versus Placebo (low dose methylene blue; 15 mg) | Crossover total: 37 BD | 27.4 \pm 7.1 | 30% | HDRS 4.9 \pm 2.9 YMRS 1.0 \pm 1.3 | Cognition was secondary outcome*: A battery including memory (CVLT) and a process-dissociation task; executive function (Trail Making Test B); selective attention (NS); negative priming (NS); inhibition of return (NS) *The primary outcome was residual mood symptoms | No significant findings. |

(Continues)

TABLE 2 (Continued)

| Author | Study design | Comparison (intervention/control) | Group | Age (mean \pm SD/median [IQR]) | Gender (% F) | Mood state at entry (scale, mean \pm SD/median [IQR]) | Neurocognitive outcome measures | Main findings |
|--------------------------|--------------------|--|-------|----------------------------------|--------------|---|---|-------------------------|
| Ciappolino et al. (2020) | RCT (Double-blind) | 12 weeks of Docosahexaenoic acid supplementation (5 capsules with 1250 mg/day) | 13 BD | 36 \pm 12 | 77% | HDRS <8 and YMRS <3 (otherwise not reported) | Primary outcome: Not specified Additional outcomes: The BAC-A including eight tests: two investigating the emotional domain, which include, (i) Affective Processing Test, which evaluates components of immediate and delayed affective and non-affective memory, and (ii) Emotion Inhibition Test, which measures the ability to suppress an automatic process, like reading, and the irrelevant elaboration of the word's meaning (affective processing) in a colour naming task, and six exploring the cognitive/linguistic domain, including, (iii) List Learning, a measure of verbal learning and memory, (iv) Digit Sequencing Task, which evaluates working memory, (v) Token Motor Task, which estimates visuo-motor abilities, (vi) Verbal Fluency, used to evaluate both semantic and phonemic fluency, (vii) Symbol-Coding Task, employed to measure attention and processing speed, (viii) Tower of London, which provides an estimation of problem-solving abilities, a subcomponent of executive functions | No significant findings |
| | | Placebo | 18 BD | 50.4 \pm 11.3 | 67% | | | |

TABLE 2 (Continued)

| Author | Study design | Comparison (intervention/control) | Group | Age (mean \pm SD/median [IQR]) | Gender (% F) | Mood state at entry (scale, mean \pm SD/median [IQR]) | Neurocognitive outcome measures | Main findings |
|----------------------|--------------------|--|--------|----------------------------------|----------------------------|--|---|--|
| Kaser et al. (2017) | RCT (Double-blind) | Single-dose of Modafinil (200 mg) Placebo | 30 MDD | 43.97 \pm 11.03 | 63% | MADRS 4.6 \pm 2.7 MADRS 4.5 \pm 3.2 | Primary outcome: Eight measures from the following four tests from the CANTAB: Paired Associates Learning, One Touch Stockings of Cambridge, Spatial Working Memory and Rapid Visual Information Processing Secondary outcomes: Nine CANTAB measures from the above four tests | Between-group ANOVA revealed significant group-by-time interactions for measures of episodic memory and working memory |
| Yatham et al. (2017) | RCT (Open-label) | 6 weeks of Lurasidone as adjunctive therapy (20–80 mg/day) TAU | 17 BD | 38.7 \pm 12.2 | 71% | MADRS 2.7 \pm 2.8 2.4 \pm 2.9 | Primary outcome: global cognition score based on the ISBD-BANC consisting of: CVLT-II trials 1–5, CVLT-II delayed free recall, BVMT-R trials 1–3, BVMT-R delayed recall, TMT-A time, TMT-B time, Continuous Performance Test – Identical Pairs trials 1–3, Animal Naming Fluency, Letter-Number Sequencing, Spatial Span, Symbol Coding, Stroop Word, Stroop Colour, and Stroop Colour-Word | Between-group ANOVA revealed significant group-by-time interactions at post-treatment on the primary global cognition outcome |
| Van Meter | RCT (Double-blind) | 8 weeks of Pramipexole (initiated at 0.125 mg/day and increased to 4.5 mg/day) 8 weeks of Placebo | 31 BD | 41.0 \pm 14.3 | 58% (across entire cohort) | HDRS 4.8 \pm 3.9 YMRS 2.7 \pm 2.4 | Primary outcome: The MCCB global composite Secondary outcome: Iowa Gambling Task Exploratory outcomes: MCCB domain scores | No significant findings |
| Smith et al. (2018) | RCT (Double-blind) | 2 weeks of Vortioxetine (20 mg/day) 2 weeks of Placebo | 24 MDD | 37.8 \pm 12.1 33.1 \pm 9 | 67% | HDRS 6.4 \pm 3.9 YMRS 2.6 \pm 2.5 HDRS 1.0 \pm 1.0 HDRS 1.6 \pm 2.1 | Cognition was secondary outcome*: A combined battery, including the following subtests: DSST, RAVLT, and Trail Making A and B *(the primary outcome was working memory-related neural activity) | Group by time ANOVA revealed an improvement in the vortioxetine on one measure of attention (Trail Making A) but no other aspects of cognition |

TABLE 2 (Continued)

| Author | Study design | Comparison (intervention/control) | Group | Age (mean ± SD/median [IQR]) | Gender (% F) | Mood state at entry (scale, mean ± SD/median [IQR]) | Neurocognitive outcome measures | Main findings |
|--------------------------|--------------------|--|--------|------------------------------|--------------|---|--|-------------------------|
| Nierenberg et al. (2019) | RCT (Double-blind) | 8 weeks of Vortioxetine (10–20 mg/day) as add-on to SSRI | 52 MDD | 45.9 ± 12.7 | 79% | HDRS 5.6 ± 2.3 | Primary outcome: Psychomotor speed (DSST) Secondary outcomes: The RAVLT acquisition and delayed recall, Trail Making A and B; The Stroop Colour naming test congruent and incongruent; Simple Reaction Time; and Choice reaction time | No significant findings |
| | | 8 weeks of Vortioxetine (10–20 mg/day) | 50 MDD | 50.6 ± 10 | 69% | HDRS 6.1 ± 2.4 | | |
| | | 8 weeks of continued SSRI treatment | 49 MDD | 47.9 ± 11.5 | 68% | HDRS 5.6 ± 2.1 | | |

Abbreviations: BAC-A, Brief Assessment of Cognition in Affective Disorder; BD, Bipolar Disorder; UD, Unipolar Disorder; F, Female; HC, healthy controls; HDRS, Hamilton depression rating scale; YMRS, Young Mania rating scale; IQR, Inter quartile range; IU, International units; RCT, Randomised controlled trial; SD, standard deviation; TAU, Treatment as usual; MCCB: MATRICS Consensus Cognitive Battery; Brief Visuospatial Memory Test, BVMT; CANTAB, Cambridge Neuropsychological Test Automated Battery; CVLT, California Verbal Learning Test; RAVLT, Rey Auditory Verbal Learning Test; DSST, Digit-Symbol Substitution Test; ISBD-BANC, International Society for Bipolar Disorders Battery for Assessment of Neurocognition; COWAT, Controlled Oral Word Association.

stimulation (rTMS) as an add-on to pharmacotherapy in partially remitted MDD or BD patients with sample sizes ranging from $n = 33$ to 52 (Table 2).^{38–40} None of the studies assessed psychosocial function or subjective cognition. One study investigated the effects of 15 20-minute sessions of prefronto-cerebellar tDCS ($n = 21$) relative to sham ($n = 21$) delivered over 3 weeks to patients with BD.³⁸ No primary cognition measure was defined a priori. All participants completed the study. The active tDCS group showed greater improvement of executive functioning and visuospatial memory than the sham group (i.e., two of five cognition measures; effect sizes not reported). However, the effects would not have survived Bonferroni adjustment for multiple comparisons. Changes over time in subsyndromal mood symptoms were not reported.

Another study investigated the effects of 10 sessions of bilateral dorsolateral prefrontal-cortex anodal tDCS over 2 weeks ($n = 18$) relative to sham ($n = 15$) in older age MDD³⁹ (Table 2). Global cognition was defined as the primary outcome and working memory as an exploratory outcome. In total, 97% of the participants completed the study. No significant effects of tDCS were found on the global cognitive composite based on a comprehensive neurocognitive test battery (see Table 2) or working memory, and no effects were observed on subsyndromal mood symptoms.

Finally, a study investigated the effects of 10 sessions high-frequency rTMS over 2 weeks ($n = 25$) relative to sham ($n = 27$) in BD.⁴⁰ It was not specified which cognition measure was the primary outcome. All the participants completed the study. The rTMS-treated patients showed greater improvement than sham-treated patients in working memory and speed of processing (two of ten cognition measures) with small effect sizes in the absence of changes in mood symptoms. However, these effects would not have survived adjustment for multiple comparisons.

Taken together, the studies showed no clear cognitive benefits; one tDCS study in MDD was negative, while the two other studies in BD (of tDCS and rTMS, respectively) showed selective treatment-related cognitive improvement that would not have survived Bonferroni correction.

3.4 | Candidate pharmacological interventions

Seven studies examined the potential cognitive benefits of add-on pharmacological interventions in partially remitted MDD or BD patients with samples ranging $N = 31–151$ (Table 2).^{41–47} Three included assessments of psychosocial function^{42,44,47} and four of subjective cognition.^{43–45,47} One crossover study in BD patients investigated the effects of methylene blue, an inhibitor of nitric oxide synthase with putative effects on neuroplasticity, which has also been found to improve hypotension. Methylene blue was administered in three doses per day for 12 weeks ($n = 17$) versus placebo ($n = 20$), with cognition measures as secondary outcomes (the primary outcome was residual mood symptoms).⁴¹ In total, 73% of the participants completed the study, with dropouts being primarily due to symptom fluctuations and mood episodes during the 6-month long trial period.




FIGURE 1 PRISMA 2020 flowchart

The study revealed no significant-related cognitive improvements after methylene blue versus placebo treatment, despite beneficial effects on residual depression and anxiety symptoms (psychosocial function not assessed).

The second study investigated the effects of docosahexaenoic acid (DHA) supplementation, which is an omega-3 fatty acid, with five capsules (1250 mg) DHA per day for 12 weeks ($n = 13$) versus placebo ($n = 18$) in BD (and in healthy controls).⁴² No cognition measure was defined as the primary outcome, and the attrition rate was also not specified. The study revealed no significant cognitive or functional improvements in DHA versus placebo-treated patients and no associations between cognition and subsyndromal mood symptoms.

The third study investigated the acute effects of a single dose of modafinil (200 mg) ($n = 30$) versus placebo ($n = 30$) in MDD.⁴³ Eight cognition measures from four computerised cognitive tests were defined as primary outcomes, while nine measures were defined as secondary outcomes. All participants completed the study. Modafinil-treated patients showed enhanced episodic memory and working memory with medium to large effect sizes relative to those given placebo but not in other aspects of cognition. These effects occurred in the absence of group differences in subsyndromal mood symptoms or subjective cognitive change and prevailed after adjustment for multiple comparisons.

The fourth study investigated the effects of 6 weeks of lurasidone ($n = 15$) versus TAU ($n = 15$) in a randomised, open-label,

outcome-assessor blind pilot study in BD, type I.⁴⁷ The primary outcome was global cognition score based on the International Society for Bipolar Disorders Battery for Assessment of Neurocognition (ISBD-BANC).⁴⁹ The study found greater global cognitive improvements in the lurasidone-treated patients than those in TAU with a large effect size. There were also significant improvements in subjective cognition but not psychosocial function in the lurasidone group compared with TAU. No concurrent change in subsyndromal mood symptoms was observed.

The fifth study investigated the effects of 8 weeks of pramipexole (initiated at 0.125 mg/day and increased to 4.5 mg/day; $n = 31$) versus placebo ($n = 29$) in fully remitted, objectively cognitively impaired patients with BD using a randomised, double-blind design. No benefits of pramipexole were observed on the primary global cognition outcome, the MCCB,⁴⁶ the secondary outcome, the Iowa Gambling Task or exploratory MCCB domain outcomes. No differences between groups were observed in mood changes over time (psychosocial function and subjective cognition were not assessed).

Finally, two studies investigated the effects of vortioxetine. One study investigated the effects of 2 weeks of vortioxetine (10–20 mg/day) ($n = 24$) versus placebo ($n = 24$) in MDD (and healthy controls) with cognition being a secondary outcome (the primary outcome was a neuroimaging-based measure of neuronal activity during working memory performance).⁴⁵ All participants completed the study. Vortioxetine improved one measure of attention in MDD patients (effect size not reported) but no other aspects of cognition,

and this effect would have not survived correction for multiple comparisons. While no effects of vortioxetine were observed on clinician-rated depression, vortioxetine-treated patients displayed improvement in self-rated depression relative to placebo-treated patients. No effects of vortioxetine were seen on patients' subjective cognition (psychosocial function not assessed). The other study investigated the effects of 8 weeks of vortioxetine (10–20 mg/day) as add-on to selective serotonin reuptake inhibitors (SSRI) ($n = 52$) or as monotherapy ($n = 50$) versus continued SSRI monotherapy ($n = 49$) in MDD.⁴⁴ Psychomotor speed (DSST) was the primary outcome, with additional measures of cognition, psychosocial function, functional capacity and subjective cognition being secondary outcomes. In total, 99% of the participants completed the study. The findings revealed no greater cognitive improvement with vortioxetine as add-on to SSRI or as monotherapy compared with the SSRI monotherapy on the primary or secondary cognition outcomes – and no differential effects on subsyndromal depression symptoms, psychosocial function, functional capacity or subjective cognition.

Taken together, the pharmacological interventions for cognitive impairments showed limited evidence. Two studies of lurasidone

or modafinil administration indicated cognitive benefits in BD and MDD, respectively, while the remaining five studies were negative.

3.5 | Risk of bias evaluation

Figure 2 displays the risk of bias evaluations of the included RCTs. Twelve studies (75%) were evaluated as involving 'some concerns' (i.e., moderate/unclear risk of bias), one (6%) as having 'high risk' of bias and three (19%) as having 'low risk of bias'. A common source of bias among the 13 studies for which cognition was the primary focus (rather than a secondary outcome), five (38%) had not selected *one primary cognition outcome* a priori, which introduced a risk of selective outcome reporting. Another common source of bias in 10 studies (62.5%) was a lack of details regarding procedures in place to ensure that the allocation sequence was concealed until participants were enrolled and assigned to interventions, which rendered it impossible to evaluate whether randomisation was truly random. Another key methodological limitation in 10 (62.5%) of the trials was the relatively small samples with $N < 60$ participants.




FIGURE 2 Risk of bias evaluations. Studies divided into cognitive remediation (first section), magnetic or direct current stimulation (second section) and pharmacological (third section) interventions and sorted alphabetically after the first author in each section

4 | DISCUSSION

This systematic review by the ISBD Targeting Cognition Task Force provides an updated overview of intervention trials targeting cognitive impairments in fully or partially remitted patients with mood disorders published after two previous systematic reviews in 2015 in BD and MDD, respectively.^{26,27} We did not conduct a quantitative meta-analysis of the evidence because of the discrepancies between interventions, study designs and treatment schedules. In total, 16 RCTs were identified; six involved cognitive remediation (CR), three involved direct current or repetitive magnetic stimulation (tDCS and rTMS) and seven involved pharmacological interventions, including methylene blue, DHA, modafinil, lurasidone, pramipexole and vortioxetine. The most consistent evidence for pro-cognitive effects comes from the CR studies, of which two were formally positive, while four showed promising effects on secondary or tertiary outcomes. In contrast, the tDCS and rTMS studies showed no evidence for efficacy on cognition. Two pharmacological interventions with modafinil and lurasidone also showed cognitive benefits. Notably, the *clinical importance* of the cognitive improvement following CR interventions, lurasidone and modafinil, is unclear because it was often not accompanied by any improvement in patients' overall functioning.

4.1 | Methodological advancements and suggestions

Most studies (81%) were evaluated as having either moderate or high risk of bias. In addition to relatively small sample sizes, the common sources of risk of bias were the absence of information on procedures in place to ensure that the allocation sequence was masked until treatment allocation and lack of pre-selection of one primary cognition outcome. In the previous systematic reviews of cognition trials in mood disorders published before 2015,^{26,27} the risk of bias was high for 44% of the RCTs. In contrast, the risk of bias was high for only one study (6%) in the present review. This indicates an overall shift in the field towards stronger methodology. Nevertheless, some challenges remain, the most notable relating to small sample sizes. Indeed, only six (37.5%) studies had sample sizes of ≥ 60 patients, of which three were of CR^{33,35,37} and three were of pharmacological treatments with modafinil, pramipexole and vortioxetine, respectively.^{43,44,46} The large reported effect sizes in the CR studies for the cognitive improvements on either primary³³ or secondary^{35,37} outcomes can thus be considered relatively robust. Further, the medium to large effect size for modafinil-induced improvement in episodic and working memory⁴³ therefore also seems robust – as do the negative findings in the pramipexole and vortioxetine studies.^{44,46} In contrast, the remaining 62.5% of trials may have had suboptimal statistical power and their predominantly negative findings should therefore be considered with caution.

The high frequency of small samples may reflect the early stage of the field, limited funding allocated to these mostly *investigator-initiated* trials with no involvement from the pharmaceutical industry (81% of trials) and suboptimal infrastructure for recruitment (i.e., single-site vs. multi-site).

Indeed, the largest study with $n = 151$ patients was designed and funded by Lundbeck and recruited patients from 17 psychiatric sites across five EU countries.⁴⁴ This indicates a need for stronger multi-site collaborations to boost sample sizes in future cognition trials. A good example is the national scientific network for mental health research, CIBERSAM, that includes 23 clinical, preclinical and translational research groups from eight communities in Spain.⁵⁰ Indeed, this network enabled several large-scale studies, including a functional remediation study in BD that included 239 patients.⁵¹ We therefore encourage national and, if possible, international collaborations, to ensure larger-scale cognition trials with adequate power.⁵² Moreover, it would be helpful to have a clear regulatory pathway for drug approval in this indication (cognitive improvement) in the context of mood disorders. This is only in place in some countries, and not for mood disorders but rather for dementia and schizophrenia. A better roadmap for marketing authorisation would likely stimulate research from pharmaceutical companies in this field.

4.2 | Cognitive remediation and strategies to aid transfer

The goal of CR is to improve *functional* outcome through training to remediate cognitive deficits.⁵³ Consequently, CR involves both direct training of cognitive functions and compensatory strategy learning, and/or transfer to real-world situations. In particular, transfer is essential to aid patients' application of trained skills to tackle cognitive challenges in daily life.⁵³ Nevertheless, only one CR study found improvement in patients' psychosocial functioning and functional capacity,³⁷ while two studies found improvements in self-reported cognition and psychological function, respectively.^{34,35} This lack of robust CR-related improvement of overall functioning is noteworthy because it puts into question the *clinical impact* of the interventions.

There are several possible reasons for the limited transfer effects to community functioning. First, patients' psychosocial impairments have multifactorial causes, with cognition being only one determinant.⁵³ Second, the instruments to measure functional changes in patients tend to index more severe levels of disability, pushing functional outcomes closer to ceiling for clinically remitted patients. Third, cognitive function is measured with *performance-based* neuropsychological tests, whereas functioning is often estimated based on *clinical interviews* or *self-ratings*, which may be influenced by a range of factors, including depression symptoms, level of insight, personality and social support. In keeping with this, studies have generally found no or only small correlations between cognition and functioning in patients with mood disorders.⁵⁴ Finally, as noted by Lewandowski and colleagues,³³ it seems insufficient to merely *discuss* with patients in CR how strategies can be applied in their daily life. Indeed, computerised training games show little resemblance to daily life challenges, such that the skills acquired therefore cannot be readily applied to daily life without therapist techniques to facilitate transfer, such as role-plays and goal setting.⁵⁵ Thus, it is pertinent that future CR involve specific and explicit implementation of strategies to aid transfer of cognitive improvements to daily life functioning. This is in line with meta-analytic

evidence from CR trials in schizophrenia spectrum disorders that the integration of *structured psychosocial rehabilitation* with CR improves transfer of cognitive gains into real-world settings.⁵⁶ Future trials in mood disorders are thus warranted to investigate whether a *combination* of functional remediation or vocational training with CR can increase transfer to daily life functioning, or whether CR programmes that embed techniques to facilitate transfer within the sessions have larger effects on psychosocial function.

4.3 | Global or selective cognition outcomes?

We previously recommended a global cognitive composite as primary outcome in cognition trials.²⁵ Six studies (38%) had defined global cognition as the primary outcome^{33–35,39,46,47} (Tables 1 and 2). This marks a clear progress from RCTs published before 2015, for which global cognition was the primary outcome in none of the trials in BD²⁶ and in only three (11%) trials in MDD.²⁷ The reason for the recommendation is partly that a broad cognitive composite score can detect small cumulative treatment effects across several cognitive tests. For example, a large improvement in the MCCB composite was observed in the trial by Lewandowski and colleagues despite no significant effect on *individual* MCCB tests, except visual learning.³³ Another reason is that improvement in global (vs. specific) cognition measures is more likely to relate to improved functioning. In keeping with this, the Food and Drug Administration (FDA) encourages the use of the MCCB cognition composite as the primary outcome in cognition trials in schizophrenia partly due to its presumed correlation with the functional capacity. Nevertheless, there are situations where a specific cognitive domain or test may be preferable as the primary outcome, namely when a treatment is believed to target a specific aspect of cognition. For example, in CR, executive function is often a core component of what is being trained and seems to be the domain that is most consistently improved across CR trials.³⁰ Based on this evidence as well as the direct influence of executive functions on real-world functioning⁵⁷ and clinical outcomes,²² this domain may thus be optimal as a primary or co-primary outcome in CR trials in which training of executive functions is a core component.

4.4 | Pre-screening for cognitive impairment

Perhaps the most important recommendation in our prior Task Force report was to pre-screen trial participants for *objective* cognitive performance deficits, to avoid enrolment of patients with no objective impairments and, hence, limited scope for improvement.²⁵ This is particularly important for trials in mood disorders because a large proportion of these patients present with *subjective* cognitive difficulties without corresponding *objective* cognitive difficulties. However, objective cognitive pre-screening was conducted in only five (31%) trials.^{34,35,44,46,47} We therefore reiterate the importance of pre-screening for objective cognitive performance deficits when designing a cognitive trial in patients with mood disorders.

Importantly, emerging evidence indicates that greater impairment *within the targeted cognitive domain* is related to greater treatment benefits in that domain.^{35,58,59} As an update of our previous recommendation, we therefore recommend that patients are pre-screened (i) for *broad* cognitive impairments in trials that select a *global* cognition composite as the primary outcome or, alternatively, (ii) for *specific* deficits in the domain selected as the primary outcome in studies of interventions with a purported specific cognitive target. Notably, efficacy of pro-cognitive interventions on global cognition may be more difficult to identify if mixed samples of patients with global and selective impairments, or of patients with only selective impairments, are included. The recommendation would be to use a different – or a parallel – version of the battery as a screener than the one used as the primary outcome. To screen for impairment in a particular domain, we recommend the use of several tests (rather than a single measure) that tap into this domain. This is because performance on a single test would be more prone to random variability associated with, for example, subsyndromal symptoms, anxiety or sleep difficulties.

4.5 | Biological interventions: Preliminary targets

The identified neuromodulation studies provided mixed and preliminary evidence. The rationale for investigating potential pro-cognitive effects of tDCS and rTMS is their assumed induction of neuroplastic changes through adjustment of the strength of synaptic transmission⁶⁰ and evidence for working memory enhancing effects in schizophrenia.⁶¹ Specifically, tDCS is presumed to enhance excitatory synaptic transmission by stimulating cortical glutamate and suppressing gamma-aminobutyric acid transmission and modulating monoamine and acetylcholine expression.⁶² However, their neurobiological mechanisms are still unclear and the evidence from the identified trials must be considered with caution.

Two^{43,47} of the seven pharmacological studies showed some cognitive benefits. Acute administration of modafinil improved episodic memory and working memory,⁴³ while 6 weeks of lurasidone improved global cognition.⁴⁷ The effects of modafinil were observed with an *acute* administration in a highly controlled setting, which renders it unclear whether *longer-term* modafinil treatment is safe or would induce lasting cognitive improvements. The cognitive benefits are likely to result from increased wakefulness due to stimulation of the histamine, noradrenaline, serotonin, dopamine and orexin systems.⁶³ While some evidence suggests that modafinil may also have neuroprotective effects,⁶³ such effects would only occur on a longer timescale. The cognitive improvement after lurasidone treatment⁴⁷ should also be interpreted with caution because of the small sample size ($N = 30$) and lack of a double-blind, placebo-controlled design. Lurasidone is a full antagonist at dopamine D2 and serotonin 5-HT2A and 5-HT7 receptors and a partial agonist at the 5-HT1A receptor,⁶⁴ which are purported mechanisms of cognitive benefits for some neuroleptic drugs.⁶⁵ While preliminary, the lurasidone-associated cognitive improvement thus provides hypothesis-generating evidence for cognitive benefits of prolonged modulation of serotonin and dopamine signalling.

Other promising pharmacological targets identified in previous systematic reviews of RCTs in mood disorders^{26,27} are: (i) the first-line Alzheimer's medication, galantamine, that inhibits breakdown of the enzyme acetylcholinesterase, (ii) the precursor for phosphatidylcholine synthesis, citicoline, that reduces cell-membrane breakdown during ischaemia, hypoxia and glutamate-mediated injury, (iii) the glucose controlling hormone, insulin, that may attenuate cerebral metabolic dysregulation, (iv) the natural herb, *Withania somnifera*, that has putative neuroprotective actions, (v) the corticosteroid receptor antagonist, mifepristone, that may counteract brain effects of hypercortisolaemia, and (vi) the multifunctional glycoprotein, EPO, that has neuroprotective and neurotrophic effects. In particular, the effects of mifepristone and EPO prevailed after Bonferroni correction for multiple comparisons, rendering these particularly promising.^{26,27}

4.6 | Future directions

Regarding directions for future cognition trials, a next important step will be to conduct *multimodal interventions* investigating the effects of combined treatments versus placebo/sham/TAU. This could be a combination of CR with functional or vocational training to aid transfer effects or of CR with pharmacological or other biological interventions that have shown some (even preliminary) cognitive benefits. Such multimodal interventions may, through complementary actions, have synergistic effects on neuroplasticity and cognition. Another promising strategy is the integration of strategies to improve sleep quality, such as therapy that targets sleep/social rhythms or chronotherapeutics, in combination with CR, to aid patients' acquisition and consolidation of trained cognitive skills. Lifestyle-based interventions (physical activity/exercise, nutrition/diet) may also – either alone or in combination⁶⁶ – be implemented in a multimodal intervention to facilitate neuroplasticity and cognitive functions.^{67,68} Indeed, the heightened risk of cardiovascular disease, diabetes and dementia in mood disorders⁶⁹ supports the implementation of such lifestyle interventions in such multimodal interventions targeting cognition. In keeping with this, the inclusion of physical exercise as an integral part of multimodal pro-cognitive interventions⁷⁰ shows promising results in schizophrenia⁷¹ and symptomatic MDD.⁷²

Finally, a recommended next step is the implementation of *neuroimaging* to investigate whether candidate pro-cognitive treatments target the aberrant neurocircuitry activity and structural abnormalities that underlie cognitive impairments.^{73,74} This will likely reveal neurocircuitry-based biomarkers that may be useful tools in treatment development strategies to screen and select among novel candidate treatments in small clinical phase 2 trials prior to commencing large-scale costly phase 3 trials.

4.7 | Limitations

The lack of a quantitative meta-analysis of the effect sizes of treatment-related cognitive improvements was a limitation. However, this was

due to the discrepancies between types of interventions, study designs and treatment schedules in the trials. Rather, our aim was to update and evaluate the quality of the evidence from RCTs and, based on this, provide updated methodological recommendations. The restriction of our search to RCTs published between 2015 and 2021 prevented a more comprehensive overview of the field. Nevertheless, an extension of the inclusion dates would have led to duplication of previous findings rather than a focused up-to-date review of the most recent evidence and current methodological challenges. The focus on remitted patients may be considered a limitation since head-to-head studies in non-remitted patients could also reveal key insights into potential pro-cognitive treatments. Specifically, if the comparison of two active treatments in acutely depressed MDD patients reveals equal antidepressant effects but greater cognitive benefits of one treatment, then this would provide promising evidence for pro-cognitive efficacy of this intervention. Such head-to-head trials with cognition as primary endpoint might be informative even if conducted with non-remitted patients, since pseudospecificity would in this way be controlled by the active comparator design,⁷⁵ as exemplified by vortioxetine trials in symptomatic MDD.⁷⁶ Nevertheless, such designs are not straight forward as it is not clear whether superiority or non-inferiority designs, influencing statistical power and sample sizes, should be preferred in relation to the antidepressant and pro-cognitive effects. Limiting the review to remitted patients can thus be considered a strength, as this addresses treatment-related improvement in the persistent trait-related cognitive deficits with a long-lasting negative impact on patients' functioning.

4.8 | Conclusions and recommendations

In conclusion, this updated systematic review of RCTs published between 2015 and 2021 identified 16 RCTs in partially or fully remitted patients with BD or UD. Six studies involved CR, three tDCS or rTMS and seven pharmacological interventions, including methylene blue, DHA, modafinil, lurasidone, pramipexole and vortioxetine. Most consistent cognitive improvements were observed with CR, with two trials being formally positive and four showing preliminary effects. In contrast, the tDCS and rTMS studies showed no cognitive benefits. Among pharmacological interventions, modafinil and lurasidone showed some cognitive benefits. Most studies had moderate risk of bias due to several common methodological challenges. As a supplement to our previous consensus-based recommendations,²⁵ we suggest that future cognition trials include: (i) increased sample sizes in trials through national and international collaborations when possible, (ii) pre-selection of one cognition outcome as primary, (iii) pre-screening for cognitive impairments within the targeted domain(s), (iv) strategies to aid transfer of cognitive gains to patients' daily lives, (v) adequate reporting of procedures for masking the allocation sequence, (vi) multimodal interventions and (vii) neuroimaging or other biomarkers to assess neurocircuitry target engagement. See the complete updated Task Force recommendations including our previous and newly added recommendations in Table 3. These include also recommendations regarding how to handle concomitant medication and

TABLE 3 Updated methodological recommendations for pro-cognitive intervention trials in mood disorders by the International Society for Bipolar Disorders Targeting Cognition Task Force

| Quick guide |
|--|
| <p>How can we enrich trials with cognitively impaired patients?</p> <ul style="list-style-type: none"> • Pre-screen participants for <i>objective</i> cognitive impairments with a brief cognition screening battery • Pre-screen for either (i) <i>broad</i> cognitive impairments in trials for which a global cognitive composite is the primary outcome or (ii) <i>specific</i> deficits in a particular cognitive domain in studies of interventions with a purported specific cognitive target • Use a <i>different</i> cognitive test battery to (or a parallel version of) the cognitive test battery implemented as the primary outcome • To screen for impairment in a particular domain, use of several tests (rather than a single test) that tap into this domain |
| <p>What is a feasible threshold for cognitive impairment?</p> <ul style="list-style-type: none"> • ≥ 0.5 SD below the normative mean for a cognitive composite based on an objective cognition screener or ≥ 1 SD below the mean on ≥ 2 single cognitive tests • If logistically feasible, cognitive impairment may be established with reference to general IQ |
| <p>Which criteria should be used to select trial participants?</p> <ul style="list-style-type: none"> • Generally, include partially or fully remitted patients in trials where cognition is primary outcome to minimise 'pseudospecificity' issues • Exclude patients with a history of moderate or severe brain injury, neurological disease, current uncontrolled thyroid condition, unstable medical illness, current or recent alcohol and substance use disorders, intellectual disability, or ECT within the past 6 months • Allow concomitant medications. These should be carefully recorded and, if possible, kept stable • In possible, disallow certain medications (e.g., high-dose antipsychotics and anticholinergic medications) • Taper benzodiazepines to a maximum dose equivalent to 22.5 mg oxazepam/7.5 mg diazepam per day and restrict use of benzodiazepine and other hypnotics six hours prior to cognitive testing • Keep serum lithium levels within the therapeutic range |
| <p>How should efficacy on cognition be assessed?</p> <ul style="list-style-type: none"> • Pre-select <i>one cognition measure</i> as the primary outcome • In general, the primary outcome should be a <i>broad</i> cognitive composite score spanning attention, verbal memory, and executive functions. Alternatively, in trials targeting a specific cognitive domain, this would ideally be a composite score based on several tests (rather than one test) tapping into this domain • Use tests that are broadly equivalent to those included in the ISBD-BANC⁴⁹ • Select key cognitive tests of interest and a functional measure as secondary outcomes |
| <p>What is a 'clinically relevant' cognitive improvement?</p> <ul style="list-style-type: none"> • Since learning effects are almost impossible to eliminate, a 'clinically relevant' effect on cognition should be estimated with reference to the cognitive change in the control group • Given the issue with learning effects (which reduce the difference between the active and control groups), small to medium effect sizes for treatment effects may be considered clinically meaningful |
| <p>How should functional implications be evaluated?</p> <ul style="list-style-type: none"> • The FAST, UPSA-B and VRFCAT are among the best measures to date for tracking changes in functional capacity associated with cognitive improvement in bipolar disorder |
| <p>How should we support transfer of cognitive gains to patients' daily lives?</p> <ul style="list-style-type: none"> • Combine pro-cognitive interventions (CR or biological treatments) with functional remediation or vocational training • Implement techniques to facilitate transfer within the CR programmes, such as role-play and goal setting |

TABLE 3 (Continued)

| |
|--|
| <p>Quick guide</p> <p>When should pre- and post-assessments be conducted?</p> <ul style="list-style-type: none"> • The optimal duration of a particular trial depends on the presumed onset of efficacy for the particular intervention based on its putative mechanisms • In general, administer biological interventions for 6–12 weeks and psychological interventions for 10–21 weeks with pre- and post-treatment assessments of cognition at baseline and immediately after treatment completion. If feasible, perform follow-up assessments after 3–6 months |
| <p>How should 'pseudospecificity' be addressed?</p> <ul style="list-style-type: none"> • Adjust the statistical analysis of cognitive change for symptom fluctuation and conduct path analysis |
| <p>What are the methodological recommendations for specific classes of agents?</p> <ul style="list-style-type: none"> • Monotherapy should only be used if the candidate treatment has mood stabilising effects for ethical reasons and to ensure generalisability. Use an active comparator drug with mood stabilising effects • Cognition trials investigating anti-psychotic, pro-dopaminergic or antidepressant drugs with efficacy on depressive symptoms should <i>ideally</i> include euthymic patients to rule out pseudospecificity. Alternatively, they can include depressed patients in a head-to-head adjunctive superiority design with a comparator without pro-cognitive effects • Trials investigating anti-inflammatory or neuroprotective drugs with limited effects on mood would benefit from expanding the inclusion criteria to partial remission in the interest of recruitment feasibility and generalisability. Use an adjunctive study design with a placebo control |
| <p>How can we ensure adequate sample sizes and, hence, optimised statistical power?</p> <ul style="list-style-type: none"> • Increase sample sizes through national and international collaborations when possible • Improving clarity on the regulatory pathway for drug approval for cognitive improvement in the context of mood disorders may also attract greater interest – and financial support – from the pharmaceutical industry |
| <p>How should statistical issues around missing data be handled?</p> <ul style="list-style-type: none"> • Intention-to-treat analyses should be implemented to prevent bias caused by dropout • Feasible ways to handle missing data with repeated assessments after treatment start are multiple imputation or mixed models |
| <p>Multimodal interventions particularly promising: why and how?</p> <ul style="list-style-type: none"> • Multimodal treatments may through synergistic effects produce stronger, longer-lasting improvements • The primary goal would be to investigate the effects of multimodal treatment versus placebo/sham/TAU • Examples are a combination of CR with: (i) functional/vocational training, (ii) biological interventions that have (even preliminary) benefits, (iii) strategies to improve sleep quality, or (iv) lifestyle-based interventions |
| <p>Neuroimaging assessments in treatment trials: why and how?</p> <ul style="list-style-type: none"> • If possible, implement neuroimaging assessments (e.g., before and after interventions) to investigate whether candidate pro-cognitive treatments target the aberrant neurocircuitry activity and structural abnormalities that underlie cognitive impairments • This will likely reveal neurocircuitry-based biomarkers that may be useful tools in treatment development strategies to improve the success rates of treatment trials |

specific classes of agents, criteria to select trial participants, how to define a 'clinically relevant' cognitive improvement, when to conduct pre- and post-assessments and how to handle statistical issues around missing data. Following these recommendations will likely improve the chances of identifying effective pro-cognitive treatments in RCTs and, thereby, accelerate the rate at which they can be integrated in the clinical management of mood disorders.

ACKNOWLEDGEMENTS

The authors thank the International Society for Bipolar Disorders executives and staff for their support of the ISBD Targeting Cognition Task Force. This work is non-funded. KWM holds a 5-year Lundbeck Foundation Fellowship (grant no. R215-2015-4121). TVR was supported by an NHMRC Early Career Fellowship (GNT1088785) and a Dame Kate Campbell Fellowship from the University of Melbourne. KD holds a Sir Charles Hercus Health Research Fellowship from the Health Research Council of New Zealand (grant no. 19/082). EV thanks the support of the Spanish Ministry of Science and Innovation (PI15/00283, PI18/00805) integrated into the Plan Nacional de I+D+I and co-financed by the ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER); the Instituto de Salud Carlos III; the CIBER of Mental Health (CIBERSAM); the Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement (2017 SGR 1365), the CERCA Programme, and the Departament de Salut de la Generalitat de Catalunya for the PERIS grant SLT006/17/00357.

CONFLICT OF INTEREST

KWM has received consultancy fees from Janssen and Lundbeck in the past 3 years. RP uses computer software at no cost for research – provided by SBT-pro and has received support for travel to educational meetings from Servier and Lundbeck. AS has received advisory or speaking fees from AbbVie, Janssen, Lundbeck, Otsuka and Sunovion in the past 3 years. KD uses computer software at no cost for research provided by SBT-pro. LVK has received consultancy fees from Lundbeck and Teva in the past 3 years. EV has received grants and served as consultant, advisor or CME speaker for the following entities: AB-Biotics, Abbott, Allergan, Angelini, Dainippon Sumitomo Pharma, Ferrer, Gedeon Richter, Janssen, Lundbeck, Otsuka, Sage, Sanofi-Aventis, Sunovion, Takeda, all them unrelated to the present work. VBM has been a consultant, advisor or Continuing Medical Education (CME) speaker over the last 3 years for the following companies: Angelini, Lundbeck, Nutrición Médica and Otsuka. AY has conducted paid lectures and advisory boards for Allergan, AstraZeneca, Bionomics, BrainCells Inc., Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Lundbeck, Novartis, Otsuka Pharmaceutical Co., Pharmaceutica, Pfizer, Roche, Sanofi-Aventis, Servier Laboratories, Sunovion and Wyeth. He was lead Investigator for the EMBOLDEN Study (AstraZeneca), BCI Neuroplasticity Study and Aripiprazole Mania Study, and has been involved in investigator-initiated studies for AstraZeneca, Eli Lilly and Wyeth. PS reports grants and non-financial support from Corcept Therapeutics, non-financial support from Janssen Research

and Development LLC, grant funding from Lundbeck and personal fees from Frontiers in Psychiatry and Allergan outside the submitted work. IJT has received has served as consultant for Lundbeck Canada, Sumitomo Dainippon and Community Living British Columbia. LNY has been on speaker/advisory boards for, or has received research grants from Alkermes, Allergan, AstraZeneca, Bristol Myers Squibb, CANMAT, CIHR, Dainippon Sumitomo Pharma, GSK, Janssen, Lilly, Lundbeck, Merck, Otsuka, Pfizer, Sanofi, Sunovion and Teva. RM has received personal fees from Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Allergan, Takeda, Neurocrine, Sunovion, Minerva, Intra-Cellular, Abbvie and Eisai and is a shareholder in the 420 Company and CEO of Champignon. AD, AC, BL, IS, MJB, CRB, CMB, KEL, PG, CLJ, AMA, SEP, TS and TVR report no conflict of interest.

ORCID

Kamilla W. Miskowiak  <https://orcid.org/0000-0003-2572-1384>
 Christopher R. Bowie  <https://orcid.org/0000-0002-1983-8861>
 Andre F. Carvalho  <https://orcid.org/0000-0002-2500-5671>
 Annemieke Dols  <https://orcid.org/0000-0003-1964-0318>
 Katie Douglas  <https://orcid.org/0000-0002-5344-2959>
 Beny Lafer  <https://orcid.org/0000-0002-6132-9999>
 Kathryn E. Lewandowski  <https://orcid.org/0000-0003-1477-6187>
 Roger S. McIntyre  <https://orcid.org/0000-0003-4733-2523>
 Richard J. Porter  <https://orcid.org/0000-0002-8695-3966>
 Ayal Schaffer  <https://orcid.org/0000-0001-6220-5042>
 Paul Stokes  <https://orcid.org/0000-0002-2274-8330>
 Tomiki Sumiyoshi  <https://orcid.org/0000-0001-9629-1671>
 Lars V. Kessing  <https://orcid.org/0000-0001-9377-9436>
 Katherine E. Burdick  <https://orcid.org/0000-0003-4417-4988>
 Eduard Vieta  <https://orcid.org/0000-0002-0548-0053>

REFERENCES

1. Barch DM. Neuropsychological abnormalities in schizophrenia and major mood disorders: similarities and differences. *Curr Psychiatry Rep.* 2009;11(4):313-319.
2. Etkin A, Gyurak A, O'Hara R. A neurobiological approach to the cognitive deficits of psychiatric disorders. *Dialogues Clin Neurosci.* 2013;15(4):419-429.
3. Rund BR, Sundet K, Asbjornsen A, et al. Neuropsychological test profiles in schizophrenia and non-psychotic depression. *Acta Psychiatr Scand.* 2006;113(4):350-359.
4. Gualtieri CT, Morgan DW. The frequency of cognitive impairment in patients with anxiety, depression, and bipolar disorder: an unaccounted source of variance in clinical trials. *J Clin Psychiatry.* 2008;69(7):1122-1130.
5. Bora E, Yucel M, Pantelis C. Cognitive endophenotypes of bipolar disorder: a meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives. *J Affect Disord.* 2009;113(1-2):1-20.
6. Bourne C, Aydemir Ö, Balanzá-Martínez V, et al. Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis. *Acta Psychiatr Scand.* 2013;128(3):149-162.
7. Dias VV, Balanzá-Martínez V, Soeiro-de-Souza MG, et al. Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview. *Acta Psychiatr Scand.* 2012;126(5):315-331.

8. Fett A-K, Viechtbauer W, Dominguez M-D-G, Penn DL, van Os J, Krabbendam L. The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. *Neurosci Biobehav Rev.* 2011;35(3):573-588.
9. Balanza-Martinez V, Crespo-Facorro B, Gonzalez-Pinto A, Vieta E. Bipolar disorder comorbid with alcohol use disorder: focus on neurocognitive correlates. *Front Physiol.* 2015;6:108.
10. Ottesen NM, Meluken I, Frikke-Schmidt R, et al. Are remitted affective disorders and familial risk of affective disorders associated with metabolic syndrome, inflammation and oxidative stress? A monozygotic twin study. *Psychol Med.* 2020;50(10):1736-1745.
11. Van Rheenen TE, McIntyre RS, Balanza-Martinez V, Berk M, Rossell SL. Cumulative cardiovascular disease risk and triglycerides differentially relate to subdomains of executive function in bipolar disorder; preliminary findings. *J Affect Disord.* 2021;278:556-562.
12. Depp CA, Mausbach BT, Harmell AL, et al. Meta-analysis of the association between cognitive abilities and everyday functioning in bipolar disorder. *Bipolar Disord.* 2012;14(3):217-226.
13. Jaeger J, Berns S, Loftus S, Gonzalez C, Czobor P. Neurocognitive test performance predicts functional recovery from acute exacerbation leading to hospitalization in bipolar disorder. *Bipolar Disord.* 2007;9(1-2):93-102.
14. McIntyre RS, Soczynska JZ, Woldeyohannes HO, et al. The impact of cognitive impairment on perceived workforce performance: results from the International Mood Disorders Collaborative Project. *Compr Psychiatry.* 2015;56:279-282.
15. Tabarés-Seisdedos R, Balanzá-Martínez V, Sánchez-Moreno J, et al. Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up. *J Affect Disord.* 2008;109(3):286-299.
16. Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jonsson B. The economic cost of brain disorders in Europe. *Eur J Neurol.* 2012;19(1):155-162.
17. Wyatt RJ, Henter I. An economic evaluation of manic-depressive illness-1991. *Soc Psychiatry Psychiatr Epidemiol.* 1995;30(5):213-219.
18. Groves SJ, Douglas KM, Porter RJ. A systematic review of cognitive predictors of treatment outcome in major depression. *Front Psychiatry.* 2018;9:382.
19. Seeberg I, Kjaerstad HL, Miskowiak KW. Neural and behavioral predictors of treatment efficacy on mood symptoms and cognition in mood disorders: a systematic review. *Front Psychiatry.* 2018;9:337.
20. Bauer IE, Hautzinger M, Meyer TD. Memory performance predicts recurrence of mania in bipolar disorder following psychotherapy: a preliminary study. *J Psychiatr Res.* 2017;84:207-213.
21. Sánchez-Morla EM, López-Villarreal A, Jiménez-López E, et al. Impact of number of episodes on neurocognitive trajectory in bipolar disorder patients: a 5-year follow-up study. *Psychol Med.* 2019;49(8):1299-1307.
22. Valerio MP, Lomastro J, Martino DJ. Neurocognitive predictors of long-term clinical course in bipolar disorder. *Aust N Z J Psychiatry.* 2020;54(11):1101-1106.
23. McIntyre RS, Berk M, Brietzke E, et al. Bipolar disorders. *Lancet.* 2020;396(10265):1841-1856.
24. Van Rheenen TE, Miskowiak K, Burdick KE. Recognising the relevance of cognitive dysfunction in the clinical management of bipolar disorder. *Bipolar Disord.* 2021;23(4):414-415.
25. Miskowiak KW, Burdick KE, Martínez-Aran A, et al. Methodological recommendations for cognition trials in bipolar disorder by the International Society for Bipolar Disorders Targeting Cognition Task Force. *Bipolar Disord.* 2017;19(8):614-626.
26. Miskowiak KW, Carvalho AF, Vieta E, Kessing LV. Cognitive enhancement treatments for bipolar disorder: a systematic review and methodological recommendations. *Eur Neuropsychopharmacol.* 2016;26(10):1541-1561.
27. Miskowiak KW, Ott CV, Petersen JZ, Kessing LV. Systematic review of randomized controlled trials of candidate treatments for cognitive impairment in depression and methodological challenges in the field. *Eur Neuropsychopharmacol.* 2016;26(12):1845-1867.
28. Tamura JK, Carvalho IP, Leanna LMW, et al. Management of cognitive impairment in bipolar disorder: a systematic review of randomized controlled trials. *CNS Spectr.* 2021;1-22.
29. Douglas KM, Van Rheenen TE. Current treatment options for cognitive impairment in bipolar disorder: a review. *Curr Treat Options Psych.* 2016;3:330-355.
30. Tsapekos D, Seccomandi B, Mantingh T, Cella M, Wykes T, Young AH. Cognitive enhancement interventions for people with bipolar disorder: a systematic review of methodological quality, treatment approaches, and outcomes. *Bipolar Disord.* 2020;22(3):216-230.
31. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ.* 2021;372:n71.
32. Gomes BC, Rocca CC, Belizario GO, et al. Cognitive behavioral rehabilitation for bipolar disorder patients: a randomized controlled trial. *Bipolar Disord.* 2019;21(7):621-633.
33. Lewandowski KE, Sperry SH, Cohen BM, et al. Treatment to enhance cognition in bipolar disorder (TREC-BD): efficacy of a randomized controlled trial of cognitive remediation versus active control. *J Clin Psychiatry.* 2017;78(9):e1242-e1249.
34. Listunova L, Kienzle J, Bartolovic M, et al. Cognitive remediation therapy for partially remitted unipolar depression: a single-blind randomized controlled trial. *J Affect Disord.* 2020;276:316-326.
35. Ott CV, Vinberg M, Kessing LV, Bowie CR, Forman JL, Miskowiak KW. Effect of Action-Based Cognitive Remediation on cognitive impairment in patients with remitted bipolar disorder: a randomized controlled trial. *Bipolar Disord.* 2021;23(5):487-499.
36. Semkovska M, Ahern E. Online neurocognitive remediation therapy to improve cognition in community-living individuals with a history of depression: a pilot study. *Internet Interv.* 2017;9:7-14.
37. Strawbridge R, Tsapekos D, Hodsoll J, et al. Cognitive remediation therapy for patients with bipolar disorder: a randomised proof-of-concept trial. *Bipolar Disord.* 2021;23(2):196-208.
38. Bersani FS, Minichino A, Bernabei L, et al. Prefronto-cerebellar tDCS enhances neurocognition in euthymic bipolar patients. Findings from a placebo-controlled neuropsychological and psychophysiological investigation. *J Affect Disord.* 2017;209:262-269.
39. Kumar S, Batist J, Ghazala Z, et al. Effects of bilateral transcranial direct current stimulation on working memory and global cognition in older patients with remitted major depression: a pilot randomized clinical trial. *Int J Geriatr Psychiatry.* 2020;35(10):1233-1242.
40. Yang L-L, Zhao D, Kong L-L, et al. High-frequency repetitive transcranial magnetic stimulation (rTMS) improves neurocognitive function in bipolar disorder. *J Affect Disord.* 2019;246:851-856.
41. Alda M, McKinnon M, Blagdon R, et al. Methylene blue treatment for residual symptoms of bipolar disorder: randomised crossover study. *Br J Psychiatry.* 2017;210(1):54-60.
42. Ciappolino V, DelVecchio G, Prunas C, et al. The effect of DHA supplementation on cognition in patients with bipolar disorder: an exploratory randomized control trial. *Nutrients.* 2020;12(3):708.
43. Kaser M, Deakin JB, Michael A, et al. Modafinil improves episodic memory and working memory cognition in patients with remitted depression: a double-blind, randomized, placebo-controlled study. *Biol Psychiatry CNI.* 2017;2(2):115-122.
44. Nierenberg AA, Loft H, Olsen CK. Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: a randomized, double-blinded, exploratory study with vortioxetine. *J Affect Disord.* 2019;250:35-42.
45. Smith J, Browning M, Conen S, et al. Vortioxetine reduces BOLD signal during performance of the N-back working memory task: a randomised neuroimaging trial in remitted depressed patients and healthy controls. *Mol Psychiatry.* 2018;23(5):1127-1133.

46. Van Meter AR, Perez-Rodriguez MM, Braga RJ, et al. Pramipexole to improve cognition in bipolar disorder: a randomized controlled trial. *J Clin Psychopharmacol*. 2021;41(4):421-427.
47. Yatham LN, Mackala S, Basivireddy J, et al. Lurasidone versus treatment as usual for cognitive impairment in euthymic patients with bipolar I disorder: a randomised, open-label, pilot study. *Lancet Psychiatry*. 2017;4(3):208-217.
48. Ciapolino V, Mazzocchi A, Botturi A, et al. The role of docosahexaenoic acid (Dha) on cognitive functions in psychiatric disorders. *Nutrients*. 2019;11(4):769.
49. Yatham LN, Torres IJ, Malhi GS, et al. The international society for bipolar disorders-battery for assessment of neurocognition (ISBD-BANC). *Bipolar Disord*. 2010;12(4):351-363.
50. Salagre E, Arango C, Artigas F, et al. CIBERSAM: Ten years of collaborative translational research in mental disorders. *Rev Psiquiatr Salud Ment*. 2019;12(1):1-8.
51. Torrent C, Bonnín CDM, Martínez-Arán A, et al. Efficacy of functional remediation in bipolar disorder: a multicenter randomized controlled study. *Am J Psychiatry*. 2013;170(8):852-859.
52. Vieta E, Angst J. Bipolar disorder cohort studies: crucial, but underfunded. *Eur Neuropsychopharmacol*. 2021;47:31-33.
53. Keefe RSE, Vinogradov S, Medalia A, et al. Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia. *Schizophr Bull*. 2011;37(5):1057-1065.
54. Ott C, Mine H, Petersen JZ, Miskowiak K. Relation between functional and cognitive impairments in remitted patients with bipolar disorder and suggestions for trials targeting cognition: an exploratory study. *J Affect Disord*. 2019;257:382-389.
55. Bowie CR, Grossman M, Gupta M, Holshausen K, Best MW. Action-based cognitive remediation for individuals with serious mental illnesses: effects of real-world simulations and goal setting on functional and vocational outcomes. *Psychiatr Rehabil J*. 2017;40(1):53-60.
56. Vita A, Barlati S, Ceraso A, et al. Effectiveness, core elements, and moderators of response of cognitive remediation for schizophrenia: a systematic review and meta-analysis of randomized clinical trials. *JAMA Psychiatry*. 2021;78(8):848.
57. Tse S, Chan S, Ng KL, Yatham LN. Meta-analysis of predictors of favorable employment outcomes among individuals with bipolar disorder. *Bipolar Disord*. 2014;16(3):217-229.
58. Burdick KE, Braga RJ, Nnadi CU, Shaya Y, Stearns WH, Malhotra AK. Placebo-controlled adjunctive trial of pramipexole in patients with bipolar disorder: targeting cognitive dysfunction. *J Clin Psychiatry*. 2012;73(1):103-112.
59. Miskowiak KW, Rush AJ, Gerds TA, Vinberg M, Kessing LV. Targeting treatments to improve cognitive function in mood disorder: suggestions from trials using erythropoietin. *J Clin Psychiatry*. 2016;77(12):e1639-e1646.
60. Nitsche MA, Liebetanz D, Antal A, Lang N, Tergau F, Paulus W. Modulation of cortical excitability by weak direct current stimulation—technical, safety and functional aspects. *Suppl Clin Neurophysiol*. 2003;56:255-276.
61. Narita Z, Stickley A, DeVylder J, et al. Effect of multi-session prefrontal transcranial direct current stimulation on cognition in schizophrenia: a systematic review and meta-analysis. *Schizophr Res*. 2020;216:367-373.
62. Yamada Y, Sumiyoshi T. Neurobiological mechanisms of transcranial direct current stimulation for psychiatric disorders; neurophysiological, chemical, and anatomical considerations. *Front Hum Neurosci*. 2021;15:631838.
63. Gerrard P, Malcolm R. Mechanisms of modafinil: a review of current research. *Neuropsychiatr Dis Treat*. 2007;3(3):349-364.
64. Meltzer HY, Share DB, Jayathilake K, Salomon RM, Lee MA. Lurasidone improves psychopathology and cognition in treatment-resistant schizophrenia. *J Clin Psychopharmacol*. 2020;40(3):240-249.
65. Sumiyoshi T. Cognitive enhancement in schizophrenia by buspirone: role of serotonin1A receptor agonism. *Schizophr Res*. 2020;215:455-456.
66. Bauer IE, Gálvez JF, Hamilton JE, et al. Lifestyle interventions targeting dietary habits and exercise in bipolar disorder: a systematic review. *J Psychiatr Res*. 2016;74:1-7.
67. Hotting K, Roder B. Beneficial effects of physical exercise on neuroplasticity and cognition. *Neurosci Biobehav Rev*. 2013;37(9):2243-2257.
68. Kandola A, Ashdown-Franks G, Hendrikse J, Sabiston CM, Stubbs B. Physical activity and depression: towards understanding the antidepressant mechanisms of physical activity. *Neurosci Biobehav Rev*. 2019;107:525-539.
69. Kessing LV, Ziersen SC, Andersen PK, Vinberg M. A nation-wide population-based longitudinal study mapping physical diseases in patients with bipolar disorder and their siblings. *J Affect Disord*. 2021;282:18-25.
70. Malchow B, Reich-Erkelenz D, Oertel-Knöchel V, et al. The effects of physical exercise in schizophrenia and affective disorders. *Eur Arch Psychiatry Clin Neurosci*. 2013;263(6):451-467.
71. Falkai P, Malchow B, Wobrock T, et al. The effect of aerobic exercise on cortical architecture in patients with chronic schizophrenia: a randomized controlled MRI study. *Eur Arch Psychiatry Clin Neurosci*. 2013;263(6):469-473.
72. Sun M, Lanctot K, Herrmann N, Gallagher D. Exercise for cognitive symptoms in depression: a systematic review of interventional studies. *Can J Psychiatry*. 2018;63(2):115-128.
73. Miskowiak KW, Petersen CS. Neuronal underpinnings of cognitive impairment and - improvement in mood disorders. *CNS Spectr*. 2019;24(1):30-53.
74. Ott CV, Johnson CB, Macoveanu J, Miskowiak K. Structural changes in the hippocampus as a biomarker for cognitive improvements in neuropsychiatric disorders: a systematic review. *Eur Neuropsychopharmacol*. 2019;29(3):319-329.
75. Vieta E, Sluth LB, Olsen CK. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: a short-term, randomized, double-blind, exploratory study versus escitalopram. *J Affect Disord*. 2018;227:803-809.
76. McIntyre RS, Harrison J, Loft H, Jacobson W, Olsen CK. The effects of vortioxetine on cognitive function in patients with major depressive disorder: a meta-analysis of three randomized controlled trials. *Int J Neuropsychopharmacol*. 2016;19(10):1-9.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher's website.

How to cite this article: Miskowiak KW, Seeberg I, Jensen MB, et al. Randomised controlled cognition trials in remitted patients with mood disorders published between 2015 and 2021: A systematic review by the International Society for Bipolar Disorders Targeting Cognition Task Force. *Bipolar Disord*. 2022;00:1-21. doi:[10.1111/bdi.13193](https://doi.org/10.1111/bdi.13193)